Key result
Obese Zucker rats exhibited a ~17% reduction in skeletal muscle microvessel density compared to lean rats prior to any blood pressure elevation, indicating rarefaction is independent of hypertension.
Why the study?
Does antihypertensive therapy with captopril or hydralazine prevent skeletal muscle microvascular rarefaction in obese Zucker rats?
Does antihypertensive therapy with captopril or hydralazine prevent skeletal muscle microvascular rarefaction in obese Zucker rats?
Effect estimate: 17% reduction at 10-11 weeks; 23% reduction at 15-17 weeks
Microvascular rarefaction in the obese Zucker rat model of metabolic syndrome occurs independently of hypertension and may be driven by other factors such as insulin resistance.
No takes yet. Share an insight, caveat, or question.
May warrant targeting insulin resistance beyond BP control in metabolic syndrome; leaves open human translation of animal findings.
Jefferson C. Frisbee (2005) studied Metabolic syndrome. Metabolic syndrome (Obese Zucker rat model) vs. Lean Zucker rats was evaluated on Skeletal muscle microvessel density (MVD) (17% reduction at 10-11 weeks; 23% reduction at 15-17 weeks). Obese Zucker rats exhibited a ~17% reduction in skeletal muscle microvessel density compared to lean rats prior to any blood pressure elevation, indicating rarefaction is independent of hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: